These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 15642496)
1. Levetiracetam in refractory epilepsy: a prospective observational study. Mohanraj R; Parker PG; Stephen LJ; Brodie MJ Seizure; 2005 Jan; 14(1):23-7. PubMed ID: 15642496 [TBL] [Abstract][Full Text] [Related]
2. Predicting drug-resistant patients who respond to add-on therapy with levetiracetam. Kinirons P; McCarthy M; Doherty CP; Delanty N Seizure; 2006 Sep; 15(6):387-92. PubMed ID: 16766211 [TBL] [Abstract][Full Text] [Related]
3. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy. Abou-Khalil B; Hemdal P; Privitera MD Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078 [TBL] [Abstract][Full Text] [Related]
4. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy. Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453 [TBL] [Abstract][Full Text] [Related]
5. Long-term effects of levetiracetam and topiramate in clinical practice: A head-to-head comparison. Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP Seizure; 2008 Jan; 17(1):19-26. PubMed ID: 17618131 [TBL] [Abstract][Full Text] [Related]
6. Levetiracetam for people with mental retardation and refractory epilepsy. Kelly K; Stephen LJ; Brodie MJ Epilepsy Behav; 2004 Dec; 5(6):878-83. PubMed ID: 15582836 [TBL] [Abstract][Full Text] [Related]
7. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study. Callenbach PM; Arts WF; ten Houten R; Augustijn P; Gunning WB; Peeters EA; Weber AM; Stroink H; Geerts Y; Geerts AT; Brouwer OF Eur J Paediatr Neurol; 2008 Jul; 12(4):321-7. PubMed ID: 17950011 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of levetiracetam as adjunctive treatment of refractory partial seizures in a multicentre open-label single-arm trial in Korean patients. Heo K; Lee BI; Yi SD; Huh K; Kim JM; Lee SA; Shin DJ; Song HK; Lee SK; Kim JY; Lu S; Dubois C; Tonner F Seizure; 2007 Jul; 16(5):402-9. PubMed ID: 17369059 [TBL] [Abstract][Full Text] [Related]
9. Loss of the initial efficacy of levetiracetam in patients with refractory epilepsy. Lee GH; Kim BM; Kang JK; Lee SA Seizure; 2013 Apr; 22(3):185-8. PubMed ID: 23280273 [TBL] [Abstract][Full Text] [Related]
10. Levetiracetam add-on therapy in Japanese patients with refractory partial epilepsy. Tanaka S; Tanaka T Epileptic Disord; 2013 Jun; 15(2):132-41. PubMed ID: 23774199 [TBL] [Abstract][Full Text] [Related]
11. Levetiracetam in children with refractory epilepsy: a multicenter open label study in Germany. Opp J; Tuxhorn I; May T; Kluger G; Wiemer-Kruel A; Kurlemann G; Gross-Selbeck G; Rating D; Brandl U; Bettendorf U; Härtel C; Korn-Merker E Seizure; 2005 Oct; 14(7):476-84. PubMed ID: 16182573 [TBL] [Abstract][Full Text] [Related]
12. Levetiracetam as add-on therapy in generalised epilepsies. Kumar SP; Smith PE Seizure; 2004 Oct; 13(7):475-7. PubMed ID: 15324824 [TBL] [Abstract][Full Text] [Related]
13. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM; Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886 [TBL] [Abstract][Full Text] [Related]
14. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. Trinka E; Marson AG; Van Paesschen W; Kälviäinen R; Marovac J; Duncan B; Buyle S; Hallström Y; Hon P; Muscas GC; Newton M; Meencke HJ; Smith PE; Pohlmann-Eden B; J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1138-47. PubMed ID: 22933814 [TBL] [Abstract][Full Text] [Related]
15. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP Epilepsy Behav; 2007 Mar; 10(2):296-303. PubMed ID: 17317325 [TBL] [Abstract][Full Text] [Related]
16. Levetiracetam in patients with refractory epilepsy: results of the SKATE trial in Austria, Germany and Switzerland. Steinhoff BJ; Trinka E; Wieser HG; Seizure; 2005 Oct; 14(7):490-6. PubMed ID: 16169256 [TBL] [Abstract][Full Text] [Related]
17. Long-term use of Levetiracetam in patients with severe childhood-onset epilepsy. von Stuelpnagel C; Holthausen H; Kluger G Eur J Paediatr Neurol; 2007 Nov; 11(6):341-5. PubMed ID: 17442601 [TBL] [Abstract][Full Text] [Related]
18. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures. Wu XY; Hong Z; Wu X; Wu LW; Wang XF; Zhou D; Zhao ZX; Lv CZ Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175 [TBL] [Abstract][Full Text] [Related]
19. The safety and efficacy of add-on levetiracetam in elderly patients with focal epilepsy: a one-year observational study. Werhahn KJ; Klimpe S; Balkaya S; Trinka E; Krämer G Seizure; 2011 May; 20(4):305-11. PubMed ID: 21257324 [TBL] [Abstract][Full Text] [Related]
20. Retention rate of levetiracetam in children with intractable epilepsy at 1 year. Peake D; Mordekar S; Gosalakkal J; Mukhtyar B; Buch S; Crane J; Wheway R; Rittey C; Donnelly J; Whitehouse WP; Philip S Seizure; 2007 Mar; 16(2):185-9. PubMed ID: 17258474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]